A Single-Center Pilot Study of Therapeutic Apheresis in Patients with Severe Post-COVID Syndrome
Hormone and Metabolic Research · 01.12.2024 · 56 (12) · 869-874
DOI: 10.1055/a-2445-8593 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hormone and Metabolic Research, erschienen am 01.12.2024. Verfasst von Johannes Korth und 5 weiteren Autor:innen. Beteiligte Einrichtung: Apherese-Zentrum am Kortumpark, Bochum, Germany. Hauptthemen laut MEDLINE: COVID-19, Blood Component Removal, Autoantibodies. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
After the COVID-19 pandemic, many patients have reported chronic fatigue and severe post-exertional malaise, with symptoms similar to those of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The accumulation of agonistic receptor autoantibodies targeting beta-adrenergic (β1 and β2) and muscarinic (M3 and M4) neurotransmitter receptors may play a crucial role in the pathomechanism of both ME/CFS and post-COVID conditions. Therapeutic apheresis has been suggested as an effective treatment option for alleviating and mitigating symptoms in this desperate group of patients. In this single-center pilot study, we analyzed autoantibodies in a cohort of 20 post-COVID patients before and after therapeutic apheresis. Apheresis resulted in a decline of β1 or β2 adrenergic receptor antibodies in all patients. Additionally, the majority of patients experienced a concurrent reduction in symptoms such as fatigue, physical activity restrictions, myalgia, post-exertional malaise, and concentration disorders. This study clearly demonstrates an association between autoantibodies and the clinical improvement of post-COVID patients. Even if future sham-controlled trials do not show a positive outcome, extracorporeal apheresis may still be valuable for this patient group by temporarily improving microperfusion and symptoms. Success in restoring patients to work and normal life, as observed in many individuals after therapeutic apheresis, should be recognized. Therefore, we believe that extracorporeal therapeutic apheresis, as part of a multimodal treatment, should be considered an early intervention for postinfectious syndromes in selected patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Apherese-Zentrum am Kortumpark, Bochum, Germany.
- Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
- Department of Cardiology, Harefield Hospital, Royal Brompton and Harefield NHS Foundation Trust Hospital, Harefield, United Kingdom of Great Britain and Northern Ireland.
- MedSelect GmbH, Lüdenscheid, Germany.
ORCID-Profile: Charlotte Steenblock
Zitieren
APA
Korth, J., Steenblock, C., Walther, R., Barbir, M., Husung, M., & Velthof, A. (2024). A Single-Center Pilot Study of Therapeutic Apheresis in Patients with Severe Post-COVID Syndrome. Hormone and Metabolic Research, 56(12), 869-874. https://doi.org/10.1055/a-2445-8593
Vancouver
Korth J, Steenblock C, Walther R, Barbir M, Husung M, Velthof A. A Single-Center Pilot Study of Therapeutic Apheresis in Patients with Severe Post-COVID Syndrome. Hormone and Metabolic Research. 2024;56(12):869-874. doi:10.1055/a-2445-8593
BibTeX
@article{Korth2024,
author = {Korth, Johannes and Steenblock, Charlotte and Walther, Romy and Barbir, Mahmoud and Husung, Michael and Velthof, Ansgar},
title = {A Single-Center Pilot Study of Therapeutic Apheresis in Patients with Severe Post-COVID Syndrome},
journal = {Hormone and Metabolic Research},
year = {2024},
volume = {56},
number = {12},
pages = {869--874},
doi = {10.1055/a-2445-8593}
}
EUVIMED